BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/25/2024 9:25:52 AM | Browse: 92 | Download: 266
 |
Received |
|
2024-01-06 14:17 |
|
Peer-Review Started |
|
2024-01-06 14:17 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-01-28 05:25 |
|
Revised |
|
2024-01-29 10:18 |
|
Second Decision |
|
2024-03-01 02:56 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-03-01 07:35 |
|
Articles in Press |
|
2024-03-01 07:35 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-12 00:33 |
|
Publish the Manuscript Online |
|
2024-06-25 09:25 |
| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Semaglutide for the management of diabesity: The real-world experience
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mohammed Alkhalifah, Hafsa Afsar, Anindya Shams, Dania Blaibel, Vishnu Chandrabalan and Joseph M Pappachan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, FRCP, MD, Academic Editor, Consultant Physician-Scientist, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane , Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Type 2 diabetes mellitus; Diabesity; Glucagon-like peptide 1 receptor agonists; Semaglutide; Insulin dose reduction; Weight loss |
| Core Tip |
Rational medical management of diabesity, i.e., diabetes resulting from obesity, involves judicious use of antidiabetic drugs which should ideally help body weight loss while controlling hyperglycemia. Although semaglutide use has been associated with significant improvements in body weight and glycated hemoglobin (HbA1c) in multiple randomized controlled trials (RCTs) and prospective observational studies, more real-world data from day-to-day medical practice would inform better clinical decision making. We report our retrospective study data that reveals better diabesity outcomes compared to RCTs with a mean weight loss of 12.3%, HbA1c reduction of 13.7% and insulin dose reduction of 19.5% with semaglutide treatment. |
| Publish Date |
2024-06-25 09:25 |
| Citation |
<p>Alkhalifah M, Afsar H, Shams A, Blaibel D, Chandrabalan V, Pappachan JM. Semaglutide for the management of diabesity: The real-world experience. <i>World J Methodol</i> 2024; 14(3): 91832</p> |
| URL |
https://www.wjgnet.com/2222-0682/full/v14/i3/91832.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v14.i3.91832 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
